1. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma;Maloney;Blood,1997
2. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis;Yoo;Ann Rheum Dis,2017
3. An introduction to biosimilar Cancer therapeutics: definitions, rationale for development and regulatory requirements;Buske;Future Oncol,2017
4. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues.. www.ema.europa.eu/docs/en_GB/document_library/Scientificguideline/2015/01/WC500180219.pdf.
5. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/05/news_detail_002747.jsp&mid=WC0b01ac058004d5c1.